Role of Cancer-associated Fibroblast, MDSCs and Immune Cell Interplays in the Resistance of Non-small Cell Lung Cancer to Anti-PD1/PD-L1 Therapies
Not yet recruiting
- Conditions
- Lung NeoplasmCancer Associated FibroblastMyeloid-Derived Suppressive Cells Immunosuppression
- Registration Number
- NCT06024538
- Lead Sponsor
- University Hospital, Bordeaux
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not yet recruiting
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Inclusion Criteria:<br><br> - consecutive patients<br><br> - lung carcinoma surgically treated by surgery only (objectives 1a and 2), or stage<br> III lung carcinoma treated by concomitant radiochemotherapy followed by durvalumab<br> (maintenance) treated between September 2018 and december 2021 (objective 1b)<br><br>Exclusion Criteria:<br><br> - patient receiving chemotherapy, radiotherapy or immunotherapy in the neoadjuvant<br> setting (all objectives)<br><br> - patient with previous cancer
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Descriptive analysis of immune infiltration and phenotypic and functional characteristics of the different cell subgroups isolated from fresh tumors
- Secondary Outcome Measures
Name Time Method Correlation between the infiltration of CAF and immunosuppressive immune cells and with clinicopathological parameters and patient prognosis (relapse free-survival, overall survival) in stage III NSCLC exposed to immunotherapy;Comparative analysis of the modifications of phenotype and functions of MDSC and T lymphocytes when exposed to CAF extracted from patient tumor tissue